Failure of rituximab in refractory erosive lichen planus

Erosive lichen planus (ELP) is a chronic inflammatory disease characterized by erosive and painful lesions affecting oral and genital mucosa, and more rarely conjunctival, auricular and esophageal mucosa and skin1 . ELP may be associated with considerable morbidity and quality of life impairment and can lead to severe complications such as vaginal and esophageal stenosis or squamous cell carcinoma1 . High-potency topical corticosteroids are considered first-line treatment options for ELP2 ; however, the use of systemic therapies such as oral corticosteroids, retinoids, hydroxychloroquine or immunosuppressive agents (including methotrexate, mycophenolate mofetil, cyclosporine, tacrolimus) are often necessary in recalcitrant cases. This article is protected by copyright. All rights reserved.